Aptose is a clinical-stage biotechnology company developing drugs for hematologic cancers, primarily acute myeloid leukemia (AML). Aptose has no approved products and no product revenue, funding operations through equity financing. Aptose's sole active clinical program is tuspetinib, a once-daily oral kinase inhibitor licensed from South Korean pharma company Hanmi in 2021 for $12.5M upfront, with up to $407.5M in future milestones and tiered royalties on net sales. Tuspetinib is being developed primarily as a frontline "triplet" combination therapy — tuspetinib + venetoclax + azacitidine — for newly diagnosed AML patients ineligible for induction chemotherapy, studied in the ongoing Phase 1/2 TUSCANY trial. The current standard of care for this population is venetoclax + azacitidine, but roughly one-third of patients don't respond and median overall survival is under 15 months. Aptose is positioning tuspetinib as a third agent to boost response rates and address venetoclax resistance. A key feature of tuspetinib's clinical profile is activity across diverse genetic mutations, making it potentially mutation-agnostic. Early TUSCANY data has shown CR/CRh rates of 90% across all dose levels, with no dose-limiting toxicities. Aptose also has a collaboration with the NCI to include tuspetinib in NCI-funded precision medicine trials. The most significant near-term development is a pending acquisition by Hanmi — the original developer of tuspetinib — in an all-cash deal approved by shareholders in March 2026 and expected to close in the first half of 2026, which would give Hanmi full global control of the asset.